Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Current Investments (2022 - 2025)

Gossamer Bio's Cash & Current Investments history spans 4 years, with the latest figure at $121.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 58.78% year-over-year to $121.4 million; the TTM value through Dec 2025 reached $121.4 million, down 58.78%, while the annual FY2025 figure was $121.4 million, 58.78% down from the prior year.
  • Cash & Current Investments reached $121.4 million in Q4 2025 per GOSS's latest filing, down from $180.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $354.5 million in Q2 2024 to a low of $121.4 million in Q4 2025.
  • Average Cash & Current Investments over 4 years is $239.8 million, with a median of $256.8 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 174.96% in 2024, then crashed 58.78% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $255.7 million in 2022, then increased by 15.94% to $296.4 million in 2023, then decreased by 0.64% to $294.5 million in 2024, then plummeted by 58.78% to $121.4 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Cash & Current Investments are $121.4 million (Q4 2025), $180.2 million (Q3 2025), and $212.9 million (Q2 2025).